Preclinical data presented at the Society for Immunotherapy of Cancer Annual Meeting show the potential of cancer-targeted myeloid cells, reprogrammed in the body through the use of chimeric antigen receptor–encoding mRNA encapsulated in lipid nanoparticles, to shrink metastases and suppress tumor growth.

You do not currently have access to this content.